First Tracks Biotherapeutics Inc (TRAX)
NASDAQ:TRAX
Want to see TRAX full AI Analyst Report?
TRAX Stock Chart & Stats
16.03
-0.34(-2.08%)
―
--
Day’s Range― - ―
52-Week Range14.72 - 26.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$559.32M
Enterprise Value385.53M
Total Cash (Recent Filing)$286.45M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.51
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding34,892,380
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.32
Forecast
1Y Price Target
$37.14Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Capital StructureThe company’s very low debt-to-equity ratio is a durable strength: it reduces bankruptcy and interest-rate sensitivity, preserves capacity to raise debt if needed, and provides financial flexibility to support R&D or bridge financing without immediate solvency pressure.
Meaningful Equity Cushion RemainsDespite declines, a multi-hundred-million dollar equity base still provides a medium-term capital buffer to fund operations and trials. This residual capital reduces immediate refinancing urgency and gives management runway to advance clinical programs before needing large external raises.
Sustained R&D / Operating InvestmentPersistent operating and R&D outlays reflect continued investment in the pipeline, a structural necessity for pre-revenue biotechs. If programs advance, these investments underpin long-term value creation and potential transition to commercial revenue over time.
Bears Say
No Revenue Across Multiple YearsAbsence of revenue is a fundamental constraint: the business remains pre-commercial and dependent on financing. Without product sales, profitability and self-sustaining cash generation are distant, making long-term viability contingent on R&D success and external capital.
Heavy And Worsening Operating Cash BurnSteadily increasing negative operating cash flow materially depletes resources and elevates the likelihood of near-term financing needs. Persistent cash burn raises dilution risk and constrains strategic optionality, making sustained execution dependent on successful capital raises.
Shrinking Equity Raises Financing/dilution RiskDeclining stockholders’ equity shows losses consuming capital; as the equity cushion erodes, the company faces heightened pressure to access markets or issue stock. That structural trend increases dilution risk and could limit long-term investment capacity.
First Tracks Biotherapeutics Inc News
TRAX FAQ
What was First Tracks Biotherapeutics Inc’s price range in the past 12 months?
First Tracks Biotherapeutics Inc lowest stock price was 14.72 and its highest was 26.80 in the past 12 months.
What is First Tracks Biotherapeutics Inc’s market cap?
First Tracks Biotherapeutics Inc’s market cap is $559.32M.
When is First Tracks Biotherapeutics Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were First Tracks Biotherapeutics Inc’s earnings last quarter?
Currently, no data Available
Is First Tracks Biotherapeutics Inc overvalued?
According to Wall Street analysts First Tracks Biotherapeutics Inc’s price is currently Undervalued.
Does First Tracks Biotherapeutics Inc pay dividends?
First Tracks Biotherapeutics Inc does not currently pay dividends.
What is First Tracks Biotherapeutics Inc’s EPS estimate?
First Tracks Biotherapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does First Tracks Biotherapeutics Inc have?
First Tracks Biotherapeutics Inc has 34,892,380 shares outstanding.
What happened to First Tracks Biotherapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of First Tracks Biotherapeutics Inc?
Currently, no hedge funds are holding shares in TRAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
First Tracks Biotherapeutics Inc Stock Smart Score
Company Description
First Tracks Biotherapeutics Inc
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
TRAX Stock 12 Month Forecast
Average Price Target
$37.14
Xencor
―
CytomX Therapeutics
―
Kura Oncology
―
Replimune Group
―
Allogene Therapeutics
―
Ownership Overview
0.33% Insiders
4.69% Mutual Funds
― Other Institutional Investors
85.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---